Drug Pricing Deals Posed as Tariff Alternative
Scott Gottlieb discussed former President Trump's use of drug pricing deals as an alternative to tariffs for reshoring pharmaceutical manufacturing. This strategy highlights a non-traditional policy tool for influencing domestic production. The approach could have broader implications for how the government incentivizes onshoring in other high-tech sectors.
- A May 5, 2025, executive order, "Regulatory Relief to Promote Domestic Production of Critical Medicines," directs the FDA and EPA to streamline permitting and inspection processes for domestic pharmaceutical facilities. The order aims to reduce the 5 to 10-year timeline currently estimated for building new manufacturing capacity in the U.S. - The U.S. is significantly reliant on foreign drug manufacturing; in 2024, the nation imported over 828,000 metric tons of pharmaceutical products, a sevenfold increase since 2000. China and India are the primary sources for the majority of U.S. generic drugs and their active pharmaceutical ingredients (APIs). - As an alternative to tariffs, the Trump administration has pursued "most-favored-nation" pricing deals with pharmaceutical companies. These agreements involve commitments from drugmakers to not charge the U.S. more for certain drugs than what other developed nations pay. - In response to the pressure of potential tariffs and these pricing discussions, several major pharmaceutical companies have announced significant investments in U.S. manufacturing. For example, Pfizer pledged a $70-billion investment in the U.S., and Swiss-based Novartis announced a $23-billion investment to establish new innovation hubs and manufacturing facilities. - The strategy of using government incentives to onshore critical manufacturing has drawn comparisons to the CHIPS and Science Act, which authorized $280 billion in new funding to boost domestic semiconductor research and production. - While not directly in semiconductor manufacturing, the Bay Area is a major hub for the biopharmaceutical industry, with over 3,000 biotechnology companies, including large firms like Genentech (a member of the Roche Group), and numerous startups in drug discovery and development. - Scott Gottlieb, a former FDA commissioner, has warned that while tariffs might incentivize branded drug manufacturers to reshore, they could lead to shortages of low-margin generic drugs. He noted that approximately 70% of the key chemical ingredients for some essential medicines, like antibiotics, originate in China.
